JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pitts, R. C.
Right arrow Articles by Dykstra, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitts, R. C.
Right arrow Articles by Dykstra, L. A.

Vol. 285, Issue 3, 1197-1206, June 1998

Clocinnamox Antagonism of the Antinociceptive Effects of Mu Opioids in Squirrel Monkeys1

Raymond C. Pitts2 , Richard M. Allen, Ellen A. Walker and Linda A. Dykstra3

Departments of Psychology (E.A.W., L.A.D.) and Pharmacology (L.A.D.), Curriculum in Neurobiology (R.M.A., L.A.D.), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and Department of Psychology (R.C.P.), University of North Carolina at Wilmington, Wilmington, North Carolina

The opioid agonists morphine, etorphine, buprenorphine and U50,488 were examined alone and in combination with the insurmountable opioid antagonist clocinnamox (C-CAM) in squirrel monkeys responding under a schedule of shock titration. In this procedure, shock intensity increased every 15 sec from 0.01 to 2.0 mA in 30 increments. Five lever presses during any given 15-sec shock period produced a 15-sec timeout, after which shock resumed at the next lower intensity. When given alone, each of these agonists increased the median intensity at which the monkeys maintained shock [median shock level (MSL)]. At the highest dose examined alone, each agonist produced maximal increases in MSL and, except buprenorphine, decreased response rates. C-CAM dose-dependently antagonized the effects of morphine, etorphine and buprenorphine on MSL. In the presence of the higher C-CAM doses, etorphine, morphine and buprenorphine did not produce maximal effects on MSL. The effects of U50,488 were not systematically altered when tested in combination with the highest C-CAM dose. In general, C-CAM was more potent and the duration of antagonism was slightly longer against buprenorphine than against morphine and etorphine. Quantitative analysis of these data according to an extended model of yielded the following apparent affinity and efficacy estimates, respectively: etorphine (0.085 mg/kg, 117); morphine (49 mg/kg, 24) and buprenorphine (0.62 mg/kg, 7.1). Determination of the individual q values over time indicated that the receptor population recovers more quickly after C-CAM antagonism of etorphine than from C-CAM antagonism of either morphine or buprenorphine. These data suggest that C-CAM functions as a long-lasting antagonist of mu opioid agonist actions in a shock titration procedure and yields estimates of relative intrinsic efficacy with the rank order of etorphine > morphine > buprenorphine.


0022-3565/98/2853-1197$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S. D. Comer, M. A. Sullivan, and E. A. Walker
Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1320 - 1330.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. M. Allen, A. L. Granger, and L. A. Dykstra
The Competitive N-Methyl-D-aspartate Receptor Antagonist (-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic Acid (LY235959) Potentiates the Antinociceptive Effects of Opioids That Vary in Efficacy at the {micro}-Opioid Receptor
J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 785 - 792.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. C. Barrett, E. S. Smith, and M. J. Picker
Use of Irreversible Antagonists to Determine the Relative Efficacy of {micro}-Opioids in a Pigeon Drug Discrimination Procedure: Comparison of {beta}-Funaltrexamine and Clocinnamox
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1061 - 1070.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. M. Allen and L. A. Dykstra
N-Methyl-D-Aspartate Receptor Antagonists Potentiate the Antinociceptive Effects of Morphine in Squirrel Monkeys
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 288 - 297.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
R. M. Allen and L. A. Dykstra
Attenuation of {micro}-Opioid Tolerance and Cross-Tolerance by the Competitive N-Methyl-D-aspartate Receptor Antagonist LY235959 Is Related to Tolerance and Cross-Tolerance Magnitude
J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1012 - 1021.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Valle, M. J. Garrido, J. M. Pavón, R. Calvo, and I. F. Trocóniz
Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effects of Main Active Metabolites of Tramadol, (+)-O-Desmethyltramadol and (-)-O-Desmethyltramadol, in Rats
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 646 - 653.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.